Weber, Walter P.
Heidinger, Martin
Hayoz, Stefanie
Matrai, Zoltan
Tausch, Christoph
Henke, Guido
Zwahlen, Daniel R.
Gruber, Günther
Zimmermann, Frank
Montagna, Giacomo
Andreozzi, Mariacarla
Goldschmidt, Maite
Schulz, Alexandra
Mueller, Andreas
Ackerknecht, Markus
Tampaki, Ekaterini Christina
Bjelic-Radisic, Vesna
Kurzeder, Christian
Sávolt, Ákos
Smanykó, Viktor
Hagen, Daniela
Müller, Dieter J.
Gnant, Michael
Loibl, Sibylle
Fitzal, Florian
Markellou, Pagona
Bekes, Inga
Egle, Daniel
Heil, Jörg
Knauer, Michael
Funding for this research was provided by:
Moritz Straus-Foundation
Fond’Action contre le cancer
Ehmann Foundation Savognin
Swiss Cancer League
Cancer League Zentralschweiz
Cancer League Thurgau
Freiwillige Akademische Gesellschaft
Kaempf-Bötschi Foundation
Swiss Cancer Research Foundation
Giuliana und Giorgio Stefanini Foundation
Miaso foundation
Krebsbekämpfung Foundation
Swiss State Secretary for Education, Research and Innovation
Association Marianne Payot
Parrotia Foundation
SPS Foundation
Rising Tide Foundation for Clinical Cancer Research
Agendia precision oncology
Fondation pour la Recherche et le Traitement Médical
Cancer League Wallis
Claudia von Schilling Foundation for Breast Cancer Research
SANA Foundation
Cancer League Basel
J and K Wonderland Foundation
Cancer League Aargau
Domarena Foundation
University of Basel
Article History
Received: 7 June 2023
Accepted: 18 September 2023
First Online: 30 October 2023
Disclosures
: W.P. Weber received research support from Agendia paid to the University Hospital Basel and honoraria for lectures from MSD. A. Mueller reports personal fees from Lilly, Novartis, Pfizer, Genomic Health, Astra Zeneca, Daiichi Sankyo, Roche, Pierre Fabre, Exact Sciences, Myriad Genetics, Gilead Sciences, Glaxo Smith Kline, MSD, GlaxoSmithKline, and grants from Roche and other from Vifor Stock. Christian Kurzeder reports honoraria from Tesaro, GSK, Astra Zeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A., Pfizer, Daichi; consulting or advisory role for Tesaro, GSK, Astra Zeneca, Novartis, PharmaMar, Genomic Health, Roche, Eli Lilly S.A., Merck MSD, Pfizer, and travel, accommodations and expenses from GSK, Astra Zeneca, and Roche. M. Gnant reports personal fees/travel support from AstraZeneca, DaiichiSankyo, EliLilly, Menarini-Stemline, MSD, Novartis, PierreFabre, Veracyte; an immediate family member is employed by Sandoz. S. Loibl reports grants from AZ, Abbvie DSI, Molecular Health, BMS/Celgene, Gilead, Novartis, Pfizer and Roche, honorarium for ad.board and presentations from AZ, Amgen, Gilead, BMS, Novartis, Pfizer, Seagen, Sanofi, Relay, Olema, Incyte, Roche, Merck KG, Lilly and GSK, non-financial medical writing support from AZ, Pfizer, Roche, Novartis, DSI, Cellcuity outside the submitted work. In addition, S. Loibl reports a patent for VM Scope with royalties paid to institute, a patent for EP14153692.0 pending, a patent for EP21152186.9 pending, and a patent for EP15702464.7 pending. F. Fitzal reports personal fees from Novartis, Astra Zeneca, Roche and MSD. D. Egle reports personal fees from AstraZeneca, Daiichi Sankyo, Gilead, MSD, Novartis, Pfizer, Sirius, and non-financial support from Roche outside the submitted work. M. Knauer reports grants from Agendia and grants from Swiss Cancer Research during the conduct of the study; other from Myriad Advisory Board outside the submitted work. All other authors report no conflicts of interest.